32 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 34558232 | A 3D-Bioprinted Multiple Myeloma Model. | 2022 Apr | 2 |
2 | 34648407 | Clinical significance of SIRT3 and inflammatory factors in multiple myeloma patients with bortezomib-induced peripheral neuropathy: a cohort study. | 2021 Dec | 1 |
3 | 31337650 | IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma. | 2019 Sep 15 | 1 |
4 | 29693175 | Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro. | 2018 Jun | 2 |
5 | 30292410 | Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo. | 2018 Nov 2 | 1 |
6 | 30455994 | Biologic Agents in the Treatment of Multicentric Castleman Disease. | 2018 Oct | 1 |
7 | 25655379 | Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. | 2015 Mar | 1 |
8 | 25791477 | Anticancer drug bortezomib increases interleukin-8 expression in human monocytes. | 2015 May 1 | 1 |
9 | 24619424 | The proteasome inhibitor bortezomib is a potent inducer of zinc finger AN1-type domain 2a gene expression: role of heat shock factor 1 (HSF1)-heat shock factor 2 (HSF2) heterocomplexes. | 2014 May 2 | 1 |
10 | 24713927 | MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. | 2014 May 22 | 1 |
11 | 24908316 | Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells. | 2014 | 1 |
12 | 25064746 | Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels. | 2014 Dec | 2 |
13 | 23063726 | Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity. | 2013 Feb | 1 |
14 | 21214673 | Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. | 2011 Apr | 2 |
15 | 20201942 | Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain. | 2010 Jun | 1 |
16 | 20663948 | Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. | 2010 Nov | 1 |
17 | 19327235 | The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. | 2009 Jan-Feb | 1 |
18 | 18316628 | Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. | 2008 May 1 | 1 |
19 | 18690088 | Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells. | 2008 Sep | 2 |
20 | 18989635 | Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma. | 2008 Nov | 1 |
21 | 19383353 | Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. | 2008 Dec | 1 |
22 | 16820206 | Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. | 2007 Apr | 2 |
23 | 17975159 | Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. | 2007 Nov 1 | 7 |
24 | 16397231 | Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. | 2006 Jan 1 | 3 |
25 | 16584593 | [Effects of proteasome inhibitor PS-341 on the multiple cytokine expressions of mesenchymal stem cells from bone marrow in patients with multiple myeloma]. | 2006 Feb | 2 |
26 | 16986718 | [Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma]. | 2006 Aug | 1 |
27 | 15090453 | Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. | 2004 Aug 1 | 2 |
28 | 15217830 | Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. | 2004 Oct 15 | 1 |
29 | 15561686 | Multiple myeloma. | 2004 | 2 |
30 | 14627979 | Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. | 2003 Nov 20 | 5 |
31 | 11306489 | The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. | 2001 Apr 1 | 2 |
32 | 11740818 | Novel therapies targeting the myeloma cell and its bone marrow microenvironment. | 2001 Dec | 3 |